Introduction
The California Perinatal Quality Care Collaborative (CPQCC) was organized in 1996 in an effort to improve perinatal outcomes in California. The strategy was based on the principle that data should inform improvement actions, adapted from the successful Vermont Oxford Network's improvement projects. [1] [2] [3] [4] [5] Using the pooled data from California's Neonatal Intensive Care Units, centers participating in the CPQCC had the opportunity to work together to identify problems, strategies for successfully overcoming them and means for implementing them locally. The process of collaboration among institutions was central to this regional effort.
The CPQCC approach relies heavily upon evidence-based toolkits that are developed by state or nationally recognized content experts on specific topics. 6 Each toolkit contains all of the components for a perinatal-neonatal unit to initiate quality improvement without painstaking and lengthy preparation. In the past, the toolkits were complemented by Quality Improvement Workshops, held throughout the state. Toolkits are divided into several sections, including evidence-based practice reviews with relevant citations and actual reprints when available for distribution, benchmarking data with instructions on how a unit can review and compare its own data with the benchmark, problem-identification worksheets for guiding chart reviews, a general structure for quality improvement followed by specific examples on how to organize teams, and appendices filled with such products as example policy and procedures, teaching aids and evaluation tools. 7 In conjunction with the toolkits, Quality Improvement Workshops are used to pull together multidisciplinary teams from the various neonatal intensive care units with the goal of improving their performance. Participants are sent pre-meeting exercises that introduce them to using the problem-identification worksheet elements of the toolkit relevant to the meeting's topics. This ensures awareness of actual unit practice and facilitates the identification of local opportunities unique to the individual units. Strategies to address specific opportunities are also facilitated at the Quality Improvement Workshops. This three step process, namely, (1) data collection and analysis; (2) toolkit development and (3) provision of workshops, has been applied successfully by CPQCC to numerous topics over the past several years. Topics have included improvements in antenatal steroid use, 8 nosocomial infection reduction, prevention of kernicterus, strategies to reduce chronic lung disease, including reduction of postnatal steroid use, management of the parenteral and enteral nutrition needs of the very low birth weight infant and prevention of Group B Streptococcus early-onset disease (GBS EOD). The remainder of this discussion will address the updated toolkit for the last of these, The Prevention of Group B Streptococcus Early Onset Disease.
Unlike most other topics addressed by the tookits, GBS EOD was not able to be benchmarked using center specific or statewide data from the CPQCC database. With an incidence between 0.5 and 1 per 1000 births, the incidence at any given center was too low to give statistical validity to a single-center data. Moreover, as only select patients greater than 1500 g were reported to the database, accurate population-based incidence was not available until 2002 when all GBS episodes became reportable. However, the Collaborative decided to include GBS EOD as one of the priorities because it remained, at the level of the statewide population, an important cause of neonatal morbidity and mortality that could be reduced by proper implementation of screening and management strategies.
Guideline statement
The following recommendations for the prevention of GBS EOD are based on critical appraisal of multistate population-based observational data and several studies from individual institutions that prompted the latest revision of the Centers for Disease Control (CDC) guideline published in 2002. 9 For this update we surveyed the literature as of October 2008 and have included several studies evaluating the impact of the 2002 guideline. When released, the 2002 guideline shifted the focus from an optional risk-based or screening-based prophylaxis strategy to an exclusive strategy of universal screening (see section Sidebar 1).
Before widespread use of intrapartum antibiotics for the prevention of GBS, invasive neonatal disease incidence ranged from 1 to 2 cases per 1000 live births, or as high as 3.6 cases when clinical sepsis and GBS colonization were included. 10, 11 This incidence decreased by approximately 70% in the mid 1990s with the implementation of intrapartum antibiotic regimens based on either risk factors or culture results. [12] [13] [14] [15] However, even with a substantial drop in the incidence of early-onset GBS disease, the residual rate of approximately 0.5 cases per 1000 live births was felt to be preventable. The adoption of the universal screening approach was based on the documentation of mothers with positive risk factors who did not receive intrapartum prophylaxis because of the absence of risk factors or failed implementation of the risk factor-based strategy. [16] [17] [18] (see section Sidebar 2).
Since the publication of the revised guideline and implementation of the universal screening for GBS in the United States, the incidence of EOD has declined further. In an analysis of CDC surveillance data comparing early-onset sepsis (EOS) in 2000 to 2001, the period immediately before the universal screening, with the postimplementation period of 2003 to 2005, the incidence was shown to decrease further by 33%. 19 Other investigators, in a single-center observational studies, have also documented significant decreases in early-onset GBS disease after the implementation of universal screening at their institutions. 20, 21 Of note, in the CDC surveillance data there appears to be a persistent and increasing trend of racial disparity in the incidence of EOS with the incidence in black infants increasing in the two reporting periods from 0.52 to 0.89 cases per 1000 live births. The incidence in white infants decreased from 0.26 to 0.22 cases per 1000 live births in the same period (see section Sidebar 3).
The strength (indicated by a letter) and quality (indicated by a roman numeral) of evidence supporting each recommendation are shown in parentheses, according to the evidence-based rating system outlined in Table 1. 9 Obstetric-care practitioners, along with supporting laboratories and labor and delivery facilities, should adopt the following strategy for the prevention of perinatal GBS disease-based on prenatal screening for GBS colonization. The riskbased approach is no longer an acceptable alternative except for circumstances in which screening results are not available before delivery (AII).
Screening indications and schedule
All pregnant women should be screened at 35 to 37 weeks' gestation for vaginal and rectal GBS colonization ( Figure 1 ) (AII). 9 At the time of labor or rupture of membranes, intrapartum chemoprophylaxis should be given to all pregnant women identified as GBS carriers (AII). Colonization during a previous pregnancy is not an indication for intrapartum prophylaxis in subsequent deliveries. Screening to detect GBS colonization in each pregnancy will determine the need for prophylaxis in that pregnancy.
Vaginal and rectal GBS screening cultures at 35-37 weeks' gestation for ALL pregnant women (unless patient had GBS bacteriuria during the current pregnancy or a previous infant with invasive GBS disease)
Intrapartum prophylaxis indicated
• Previous infant with invasive GBS disease
• GBS bacteriuria during currentpregnancy
• Positive GBS screening culture during current pregnancy (unless a planned cesarean delivery, in the absence of labor or amniotic membrane rupture, is performed)
• Unknown GBS status (culture not done, incomplete, or results unknown) and any of the following:
• Delivery at <37 weeks' gestation* • Amniotic membrane rupture ≥18 hours
• Intrapartum temperature ≥100.4°F (≥38.0°C) †
Intrapartum prophylaxis not indicated
• Previous pregnancy with a positive GBS screening culture (unless a culture was also positive during the current pregnancy) •
• Negative vaginal and rectal GBS screening culture in late gestation during the current pregnancy, regardless of intrapartum risk factors
Planned cesarean delivery performed in the absence of labor or membrane rupture (regardless of maternal GBS culture status) Figure 1 Indications for intrapartum antibiotic prophylaxis to prevent perinatal Group B Streptococcus (GBS) disease under a universal prenatal screening strategy based on combined vaginal and rectal cultures collected at 35 to 37 weeks' gestation from all pregnant women. *If onset of labor or rupture of amniotic membranes occurs at <37 weeks' gestation and there is a significant risk for preterm delivery (as assessed by the clinician), a suggested algorithm for GBS prophylaxis management is provided ( Figure 2 ). w If amnionitis is suspected, broad-spectrum antibiotic therapy that includes an agent known to be active against GBS should replace GBS prophylaxis. Women with GBS isolated from the urine in any concentration during their current pregnancy should receive intrapartum chemoprophylaxis, because such women usually are heavily colonized with GBS and are at increased risk of delivering an infant with early-onset GBS disease (BII). Labels on urine specimens from prenatal patients should clearly state the patient's pregnancy status to assist laboratory processing and reporting of results. Prenatal culture-based screening at 35 to 37 weeks' gestation is not necessary for women with GBS bacteriuria. Women with symptomatic or asymptomatic GBS urinary tract infection detected during pregnancy should be treated according to the current standards of care for urinary tract infection during pregnancy (see section Sidebar 4).
Women who have previously given birth to an infant with invasive GBS disease should receive intrapartum chemoprophylaxis; prenatal culture-based screening is not necessary for these women (BII). If the result of GBS culture is not known at the onset of labor, intrapartum chemoprophylaxis should be administered to women with any of the following risk factors: gestation <37 weeks, duration of membrane rupture >18 h or a temperature of >100.4 1F (>38.0 1C) (AII) (see section Sidebar 5). Women with known negative results from vaginal and rectal GBS screening cultures within 5 weeks of delivery do not require prophylaxis to prevent GBS disease even if any of the intrapartum risk factors develop. Women with threatened preterm (<37 weeks' gestation) delivery should be assessed for need for intrapartum prophylaxis to prevent perinatal GBS disease. An algorithm for the management of women with threatened preterm delivery is provided ( Figure 2 ). 9 Other management approaches, developed by individual physicians or institutions, may be appropriate (CIII). Culture techniques that maximize the likelihood of GBS recovery are required for prenatal screening. 9 Collection of specimens for culture may be conducted in the outpatient clinic setting by either the patient, with appropriate instruction, or health-care provider (BII). This involves swabbing the lower vagina and rectum (that is, through the anal sphincter). Because lower vaginal as opposed to cervical cultures are recommended, cultures should not be collected by speculum examination. Specimens should be placed in a nonnutritive transport medium (for example, Amies or Stuart's without charcoal). Specimen labels should clearly identify that specimens are for GBS culture. If susceptibility testing is ordered for penicillin-allergic women (Box 1), 9 specimen labels should also identify the patient as penicillin allergic and should specify that if GBS is isolated, it should be tested for susceptibility to clindamycin and erythromycin. Specimens should be inoculated into a selective broth medium (examples of appropriate commercially available media include Trans-Vag Broth supplemented with 5% defibrinated sheep blood or LIM broth), incubated overnight, and subcultured onto solid blood agar medium (AII). Methods of testing prenatal isolates from penicillinallergic women for susceptibility to clindamycin and erythromycin are outlined in the CDC guideline. 9 Laboratories should report culture results (positive and negative) and susceptibility testing results to the anticipated site of delivery (when known) and to the health-care provider who ordered the test. Health-care providers should inform women of their GBS screening test result and the recommended interventions. In the absence of GBS urinary tract infection, antimicrobial agents should not be used before the intrapartum period to treat GBS colonization. Such treatment is not effective in eliminating carriage or preventing neonatal disease and may cause adverse consequences resulting from overtreatment with antibiotics (DI). Group B Streptococcus-colonized women who have a planned cesarean delivery performed before rupture of membranes and onset of labor are at low risk for having an infant with earlyonset GBS disease. These women should not routinely receive intrapartum chemoprophylaxis for perinatal GBS disease prevention (CII). For intrapartum chemoprophylaxis, the following regimen is recommended for women without penicillin allergy (Box 1): penicillin G, 5 million units intravenously initial dose, then 2.5 million units intravenously every 4 h until delivery (AII). 9 Because of its narrow spectrum of activity, penicillin is the preferred agent. An alternative regimen is ampicillin, 2 g intravenously initial dose, then 1 g intravenously every 4 h until delivery (AI). Intrapartum chemoprophylaxis for penicillin-allergic women takes into account increasing the resistance to clindamycin and erythromycin among GBS isolates (Box 1). 9 During prenatal care, history of penicillin allergy should be assessed to determine whether a patient is at high risk for anaphylaxis, that is, has a history of immediate hypersensitivity reactions to penicillin (for example, anaphylaxis, angioedema or urticaria) or history of asthma or other conditions that would make anaphylaxis more dangerous. Women who are not at high risk for anaphylaxis should be given cefazolin, 2 g intravenously initial dose, then 1 g intravenously every 8 h until delivery (BIII) (see section Sidebar 6) . For women at high risk for anaphylaxis, clindamycin and erythromycin susceptibility testing, if available, should be performed on isolates obtained during GBS prenatal carriage screening. Women with clindamycin-and erythromycin-susceptible isolates should be given either clindamycin, 900 mg intravenously every 8 h until delivery; or erythromycin, 500 mg intravenously every 6 h until delivery. If susceptibility testing is not possible, susceptibility results are not known, or isolates are resistant to erythromycin or clindamycin, the following regimen can be used for women with immediate penicillin hypersensitivity: vancomycin, 1 g intravenously every 12 h until delivery (CIII). Routine use of antimicrobial prophylaxis for newborns whose mothers received intrapartum chemoprophylaxis for GBS infection is not recommended. However, therapeutic use of these agents is appropriate for infants with clinically suspected sepsis. An updated algorithm for the management of infants born to mothers who received intrapartum chemoprophylaxis for GBS infection is provided in the CDC guideline. 9 This revised algorithm is not an exclusive approach to management; variation that incorporates individual circumstances or institutional preferences may be appropriate (CIII) (see section Sidebar 7). Local and state public health agencies, along with appropriate groups of hospitals, are encouraged to establish surveillance for early-onset GBS disease and to take other steps to promote perinatal GBS disease prevention and education to reduce the incidence of early-onset GBS disease in their states. Efforts to monitor the emergence of perinatal infections caused by other organisms are also encouraged. Before full implementation of this strategy can be expected in all health-care settings, all members of the health-care team will need to improve protocols for isolation and reporting of GBS culture results, to improve information management to ensure communication of screening results and to educate medical and nursing staff responsible for prenatal and intrapartum care. Within institutions, such efforts may take several months. Even with ideal implementation, cases of early-onset GBS disease will continue to occur (see section Sidebar 8).
Additional educational and quality improvement materials Tools to help promote prevention and educate parents of infants with early-onset GBS disease are available at http://www.cdc.gov/ groupbstrep. Additional tools available to assist with prevention implementation are available at http://www.acog.org, Multiple copies of educational materials published by CDC are available at the Public Health Foundation, 1220L Street, NW Suite 350, Washington, DC 20005, telephone 877-252-1200, or online at http://bookstore.phf.org/advanced_search_result.php?keywords ¼ Group+B+strep&x ¼ 5&y ¼ 7
The Centers for Disease Control, the American College of Obstetrics and Gynecology and the American Academy of Pediatrics websites have a variety of materials available to help with implementation.
The CDC site (http://www.cdc.gov/groupbstrep) contains the following:
the Guidelines themselves Clinical Issues and Introduction to the New Guidelines Slide presentation geared toward health professionals that covers background on the epidemiology of perinatal GBS disease, the impact of prevention efforts in the 1990s, the rationale for revisions to the 1996 guidelines, and the recommendations in the CDC's 2002 guidelines. This is a downloadable powerpoint file and each slide includes brief speaker notes. A parent information sheet Group B Streptococcus and Pregnancy This pamphlet discusses the ways to help prevent GBS infection in newborns.
Supplementary material
The appendix (Supplementary Material Appendix) contains numerous supportive tools to assist local implementation of the guideline. There are fishbone diagrams outlining the process of implementation and problem identification worksheets to be used in local quality improvement projects involved with reducing the incidence of GBS EOD.
Future directions
Rapid detection methodology Efforts to address the residual incidence of GBS EOD have prompted further analysis of the underlying causes for the failure of current prevention strategies. As discussed earlier (Sidebar 8, Persistent GBS Disease with Screening Protocols), the CDC reports that post-implementation monitoring in the period after the universal screening was recommended shows a residual incidence of GBS EOD to be approximately 0.5 cases per 1000 live births overall, and up to 0.89 cases per 1000 live births among African Americans. It has been shown that intrapartum antibiotic prophylaxis is almost 100% effective in eliminating vertical transmission of GBS in colonized mothers, eliminating this phase of the guideline as a source of screening failures. [22] [23] [24] [25] Numerous problems in identification of colonized mothers continue to exist. These are based on failures to screen, errors in tracking of results or the inherent limitations of antepartum cultures because of the intermittent nature of GBS colonization leading to false-negative screening tests. Puopolo et al. 26 showed that in term infants with GBS EOD in the post-universal screening era, 82% of the mothers had negative rectovaginal cultures on antenatal screening. In early studies establishing the groundwork for GBS prevention protocols, Boyer et al.
showed that when compared with intrapartum cultures, antenatal screening for GBS only had a positive predictive value of 72.5% and a negative predictive value (NPV) of 91.5%. These values were for cultures obtained at any time before delivery. These data also showed an inverse relationship with the interval between prenatal cultures and delivery, that is, the accuracy improved the closer to delivery cultures were obtained. 25 In several more recent studies, the relationship between screening cultures for GBS at 35 to 37 weeks and at delivery has been shown to have a positive predictive value of 67 to 87%, and an NPV of 91 to 96%. [27] [28] [29] Thus, 67 to 87% of mothers may be unnecessarily exposed to intrapartum antibiotics when they are not colonized at the time of delivery, and more importantly, 4 to 9% of mothers who are colonized at the time of delivery would miss intrapartum prophylaxis because their antenatal screening was negative.
One solution to this inherent problem with protocols based on antepartum screening is to use rapid intrapartum screening to identify only those mothers who are colonized at the time of delivery. Such a test would need to have a high NPV, so false negatives are essentially eliminated and have a reasonably high positive predictive value to avoid unnecessary intrapartum antibiotic administration. Such a test would also need to have rapid turnaround and be available 24 h day À1 , so colonized mothers could be identified more than 4 h before delivery to make the prophylaxis effective. Rapid testing for GBS colonization using rectovaginal specimens has been studied extensively. Rapid testing technology has evolved to a point where numerous independent investigators are consistently reporting accuracy much better with DNA PCR assays than with antepartum screening. These are recent reports, describing the likely evolution of DNA PCR technology that may be available in the near future. Sensitivity and specificity are reported in the range of 91 to 97% and 96 to 99%, respectively. Positive predictive value and NPV for real-time DNA PCR assays are reported to be in the range of 88 to 98% and 97 to 98%, respectively. 30, 31 DNA PCR results are also reported to be available within less than 2 h and can be performed on the maternal unit, thus satisfying more essential requirements of a rapid screening test for GBS. [31] [32] [33] Although very promising, further evaluation of accuracy, feasibility and cost-effectiveness will still be necessary in larger population studies before these tests will replace the current antepartum screening protocols.
Group B Streptococcal vaccines
An effective vaccine against GBS would eliminate the need for risk-based and screening-based guidelines with their attendant limitations. It could also have additional benefits in preventing GBS-related stillbirths or prematurity by providing protection earlier in the gestation than the intrapartum prophylaxis strategies. It would provide a longer duration of immunity to the newborn, thus preventing late-onset GBS as well. Finally, an effective vaccine would also protect the mother against invasive GBS infection. 34 The ideal GBS vaccine would be administered only once, before or during pregnancy. If given during pregnancy, it would need to have proven safety without toxicity or teratogenicity. Ideally, it would eliminate or reduce colonization with GBS in the maternal gastrointestinal and reproductive tract, reducing the risk of late-onset disease GBS, stillbirths resulting from GBS infection and EOD in premature infants born before placental antibody transfer.
The surface of the GBS organism is made up of the unique group-specific carbohydrate and a number of type-specific polysaccharides, Types I through VII. The capsular polysaccharide antigens are immunogenic, and susceptibility of the newborn to clinical disease is associated with levels of antibody to the different capsular polysaccharides. [35] [36] [37] In the United Kingdom and North America, EOD is associated with Type Ia, III and V, whereas late-onset disease is associated primarily with Type III. Polysaccharide antigen prevalence varies in other regions of the world, with reports of predominance of colonization with serotypes VI and VIII in Japan, Ib, Ic, II and III in the Netherlands and V in Gambia. [38] [39] [40] [41] The immunogenicity of capsular polysaccharides and the relationship of certain serotypes to specific disease manifestations make the development of a GBS vaccine a feasible and desirable approach to prevention of disease. As all of the serotypes are associated with disease, vaccines would need to be multivalent, covering the serotypes prevalent in the specific region.
The current vaccine research and development is based on targeting of the capsular polysaccharides. The different carbohydrate molecules are bonded with protein carriers, most commonly tetanus toxoid, to enhance immunogenicity of the vaccine. Numerous Phase I and Phase II studies in humans have shown successful immunogenicity of these capsular polysaccharide-tetanus toxoid conjugate vaccines in healthy adult volunteers 42, 43 and in pregnant women. 36, 44 Vaccines will not be ready for widespread distribution until Phase III testing has been completed with larger multicenter randomized controlled trials. Clinical research at this level will entail significant obstacles. As the background incidence of GBS is so low, at least 40 000 women would need to be enrolled for an 80% probability of showing a significant reduction in GBS disease. As the standard prevention strategies involving intrapartum antibiotic prophylaxis are reasonably successful, this treatment cannot be withheld in a vaccine trial. Any Phase III trial will need to show incremental efficacy in patients already receiving intrapartum antibiotic prophylaxis, making the trial even larger. Another obstacle to the approval of a GBS vaccine is the need for administration during gestation. Owing to the background incidence of congenital malformations and stillbirths, the liability of testing a vaccine in the pregnant population presents overwhelming liability challenges, considering the fact that there is currently no legal protection for companies or institutions sponsoring such research. Some experts feel that the regulatory and legal challenges are too great to allow further progress in implementation of a GBS vaccine. 34 
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